论文部分内容阅读
目的 :研究中药 96 0合剂内服配合肝动脉栓塞化疗 (TACE)治疗晚期肝癌的临床疗效。方法 :不宜手术的原发性肝癌患者 95例 ,随机分成 A组 (47例 ) :常规 TACE加中药 96 0合剂 ,介入前 7d开始服药。B组 (48例 ) :单纯 TACE。结果 :1A组肝区疼痛 ,乏力 ,食欲不振 ,腹胀 ,腹水等临床症状明显改善 ,体重增加 ,Karnofsky积分等生活质量指数显著优于 B组。 2 A组无明显肝功能急性损伤 ,部分病例肝功能较前改善 ,血清肝纤维化指标均有所降低。B组部分病例肝功能恶化 ,血清肝纤维化指标无改善。 3A组完全缓解 (CR) 5例 ,部分缓解 (PR) 2 0例 ,无变化 (NC) 16例 ,进展 (PD) 6例 ,有效率 87.2 3% ;B组分别为 3例、18例、18例、9例、81.2 5 %。两组比较差异无显著性意义。 4 A组 1、2、3年生存率 (6 1.4 %、31.5 %和 17.7% )显著优于 B组 (32 .6 %、2 3.5 %和 8.9% )。结论 :TACE配合应用 96 0合剂 ,患者临床症状改善 ,生存质量提高 ,生存期延长 ,提高了介入治疗效果 ,对晚期肝癌特别是伴有肝纤维化者尤为适宜。
Objective: To study the clinical efficacy of Chinese herbal medicine 96 0 combined with oral administration of transcatheter arterial chemoembolization (TACE) in the treatment of advanced liver cancer. Methods: Ninety-five patients with primary hepatocellular carcinoma not suitable for surgery were randomly divided into group A (n = 47): conventional TACE plus Chinese herbal medicine 96 0 mixture, and medication was started 7 days before the intervention. Group B (48 cases): simple TACE. Results: The clinical symptoms such as abdominal pain, ascites, appetite, bloating and ascites in Group 1A were significantly improved. The weight gain and Karnofsky score were significantly better than Group B in quality of life. There was no obvious acute liver injury in group A, the liver function in some cases was improved, and the serum liver fibrosis index was decreased. Some patients in group B had worse liver function and no improvement in serum liver fibrosis. In group 3A, there were 5 cases of complete remission (CR), 20 cases of partial remission (PR), 16 cases of no change (NC) and 6 cases of progression (PD), the effective rate was 87.2% 18 cases, 9 cases, 81.2 5%. There was no significant difference between the two groups. The 1, 2, 3 year survival rates of group A were significantly higher than those of group B (32.6%, 23.5% and 8.9%). Conclusion: TACE with 96 0 mixture, the clinical symptoms of patients improve quality of life, prolong survival and improve the effect of interventional treatment of advanced liver cancer, especially with liver fibrosis are particularly suitable.